Furthermore, EGF‑ETA was just as potent in HCT116 (KRAS G13D) and SW480 (KRAS G12V) colon cancer cell lines harbouring KRAS hyperactivating mutations when compared to KRAS wild‑type HT29 colon cancer cells.
According to our results, EGF-modified nanospheres containing bufalin show improved anti-tumor effects on colon cancer in nude mice, but without severe side effects.